Qiagen NV (QGEN) Shares Bought by Bank of Montreal Can

Bank of Montreal Can increased its holdings in Qiagen NV (NASDAQ:QGEN) by 10.2% during the third quarter, HoldingsChannel reports. The firm owned 815,525 shares of the company’s stock after acquiring an additional 75,638 shares during the quarter. Bank of Montreal Can’s holdings in Qiagen were worth $30,892,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of QGEN. Lourd Capital LLC bought a new stake in Qiagen in the 3rd quarter worth approximately $250,000. State of Alaska Department of Revenue increased its stake in Qiagen by 40.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 23,084 shares of the company’s stock worth $874,000 after acquiring an additional 6,633 shares during the last quarter. Private Trust Co. NA bought a new position in shares of Qiagen during the 3rd quarter valued at approximately $233,000. Fox Run Management L.L.C. increased its position in shares of Qiagen by 254.6% during the 3rd quarter. Fox Run Management L.L.C. now owns 23,151 shares of the company’s stock valued at $877,000 after purchasing an additional 16,623 shares during the last quarter. Finally, Exane Asset Management increased its position in shares of Qiagen by 17.0% during the 2nd quarter. Exane Asset Management now owns 761,887 shares of the company’s stock valued at $29,296,000 after purchasing an additional 110,651 shares during the last quarter. 62.23% of the stock is currently owned by institutional investors.

Several equities analysts have recently weighed in on the company. BidaskClub raised Qiagen from a “sell” rating to a “hold” rating in a research report on Wednesday, August 29th. Commerzbank reissued a “buy” rating on shares of Qiagen in a research report on Wednesday, August 29th. Barclays reissued a “buy” rating and set a $43.00 target price on shares of Qiagen in a research report on Thursday, September 6th. Zacks Investment Research raised Qiagen from a “sell” rating to a “hold” rating in a research report on Friday, August 3rd. Finally, Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research report on Friday, August 3rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. Qiagen has a consensus rating of “Hold” and an average target price of $38.88.

NASDAQ QGEN opened at $35.91 on Friday. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69. Qiagen NV has a fifty-two week low of $30.20 and a fifty-two week high of $39.45.

Qiagen (NASDAQ:QGEN) last announced its quarterly earnings data on Tuesday, July 31st. The company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.32 by $0.01. The company had revenue of $377.20 million for the quarter, compared to the consensus estimate of $376.89 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. As a group, equities research analysts expect that Qiagen NV will post 1.34 earnings per share for the current fiscal year.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

See Also: Market Capitalization – What it Means for Investors

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).

Institutional Ownership by Quarter for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply